Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2005

01-09-2005 | Article

Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors

Authors: A. M. Hennige, V. Strack, E. Metzinger, G. Seipke, H.-U. Häring, M. Kellerer

Published in: Diabetologia | Issue 9/2005

Login to get access

Abstract

Aims/hypothesis

New insulin analogues have been created by amino-acid exchange to provide an improved pharmacokinetic profile. However, safety issues have been raised regarding their use, as amino-acid exchange of insulin may induce altered metabolic and mitogenic effects. For example, the insulin analogue Asp(B10) causes breast cancer in rodents. The aim of this study was to compare two new insulin analogues HMR1964 (Lys[B3],Glu[B29]) (insulin glulisine) and HMR1423 (Gly[A21],His[B31],His[B32]) with regular insulin and the mitogenic analogue Asp(B10).

Materials and methods

We analysed insulin receptor binding characteristics and dissociation kinetics, as well as insulin-induced receptor auto- and dephosphorylation kinetics, in rat-1 fibroblasts overexpressing the human insulin receptor isoform B. Mitogenic activity was tested in the non-malignant cell line MCF10.

Results

Regular insulin, HMR1964 and HMR1423 showed no significant differences in receptor association, dissociation and receptor binding affinity, while Asp(B10) displayed markedly increased insulin receptor affinity. All of the analogues induced rapid insulin receptor autophosphorylation, reaching a maximum 10 min after stimulation (10−9 mmol/l insulin). In contrast, Asp(B10) induced a prolonged phosphorylation and dephosphorylation state of the 95 kDa insulin receptor β-subunit. With respect to [3H]thymidine incorporation, the new analogues had similar (HMR1423) or even lower (HMR1964) effects than regular insulin in the mammary epithelial cell line MCF10, while Asp(B10) showed increased [3H]thymidine incorporation.

Conclusions/interpretation

HMR1964 and HMR1423 displayed the same association, dissociation and insulin receptor affinity kinetics as regular insulin, and might therefore be useful for the treatment of diabetes.
Literature
1.
Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA (1999) Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42:1151–1167CrossRefPubMed
2.
Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396–402PubMed
3.
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time–action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMed
4.
Setter SM, Corbett CF, Campbell RK, White JR (2000) Insulin aspart: a new rapid-acting insulin analog. Ann Pharmacother 34:1423–1431PubMed
5.
Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMed
6.
Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [B10-aspartic acid]insulin(human). Proc Natl Acad Sci U S A 84:6408–6411PubMed
7.
Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488–1495PubMed
8.
Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313PubMed
9.
Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, Duckworth WC (1999) Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 48:611–617CrossRefPubMed
10.
Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU (1998) The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123–129PubMed
11.
Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40:54–61CrossRef
12.
Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259–285PubMed
13.
Soule HD, Maloney TM, Wolman SR et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF10. Cancer Res 50:6075–6086PubMed
14.
Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18:19–25CrossRefPubMed
15.
Kurtzhals P, Schaffer L, Sorensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMed
16.
Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279PubMed
17.
Denley A, Wallace JC, Cosgrove LJ, Forbes BE (2003) The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 35:778–785CrossRefPubMed
18.
Rakatzi I, Ramrath S, Ledwig D et al (2003) A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227–2238PubMed
Metadata
Title
Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors
Authors
A. M. Hennige
V. Strack
E. Metzinger
G. Seipke
H.-U. Häring
M. Kellerer
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1870-8

Other articles of this Issue 9/2005

Diabetologia 9/2005 Go to the issue

Article

Interstitial fluid glucose dynamics during insulin-induced hypoglycaemia

Article

The effect of HLA class II, insulin and CTLA4 gene regions on the development of humoral beta cell autoimmunity

Article

Marked differences in the IGF system that are associated with migration in comparable populations of Gujaratis living in Sandwell, UK, and Gujarat, India

Short communication

Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass

Letter

Should seven be the magic number of type 2 diabetes?

Article

Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits